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Incubation of C6-2B rat  glioma cells  with UDP or UTP 
resulted in a time- and concentration-dependent in- 
crease  in  the  accumulation of inositol phosphates. In 
contrast, ATP, ADP, and analogs of these nucleotides 
known to  be  effective  agonists  at Pzv-, Pm-,  P,,-,  P,,-,  and 
P,,-purinergic receptors all had no effect on inositol 
phosphate  levels  in C6-2B cells.  Pyrimidine  nucleotides 
stimulated  inositol  phosphate  accumulation  with  an  or- 
der of potency of UDP > 5-BrUTP > UTP > dTDP > UDP 
glucose. values for UDP, 5-BrUTP, and UTP were 2.3 
* 0.5,9 * 3,  and  57 10 m, respectively. A similar  uridine 
nucleotide  selectivity  was  observed  for  arachidonic  acid 
release  presumably  occurring  as a  consequence  of acti- 
vation of phospholipase 4. Cross-desensitization and 
additivity  experiments  indicated  that UDP  and  UTP in- 
teract  with  the  same  population f receptors.  The  effect 
of uridine  nucleotides on inositol  phosphate  accumula- 
tion was inhibited markedly by pretreatment of cells 
with  pertussis  toxin. UDP also caused  a  guanine  nucle- 
otide-dependent  increase  in  inositol  lipid  hydrolysis  in 
streptolysin-0-permeabilized cells. Taken  together 
these  results  describe  the  existence of a novel  uridine 
nucleotide receptor that is not activated by adenine 
nucleotides.  This  receptor is pharmacologically  distinct 
from  the  previously  described  P2”-  and  other  P,-puriner- 
gic  receptors,  and  likely is a member of a new  class of 
receptors  for  extracellular  nucleotides. 
Extracellular  release of adenine nucleotides  from neurons, 
platelets, and other tissues results in activation of a broad 
range of physiological responses (1, 2). Considerable  progress 
has  been  made  in  the  last decade in  the pharmacological de- 
lineation of the cell surface receptors that are activated by 
extracellular ATP and ADP. These P,-purinergic receptors in- 
clude the P,,-, P,,-, P,,-, P,,-, and P,,-receptors, which are 
selectively activated by ATP,  ADP, or various  analogs of these 
two adenine nucleotides (1-3). The one exception to  the  adenine 
nucleotide selectivity of these receptors is  the so-called P,,- 
purinergic receptor, which is not only activated by ATP and 
ATPyS,’ but  also  is  stimulated by the pyrimidine, UTP (4-8). 
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Although care has been  taken  to prove that  the P,,-purinergic 
receptor that  stimulates inositol  lipid  hydrolysis in man.y tar- 
get  tissues is a single  receptor activated by both ATP and  UTP 
(8,9), this does not  rule  out  the possibility that separate recep- 
tors for purines  and pyrimidines occur. Indeed,  studies  meas- 
uring  vascular smooth  muscle responses (10-12) or metabolic 
effects in  liver (13) and  in  neutrophils or HL-60 cells (14, 15) 
have led to  the proposal that “pyrimidinergic”  receptors exist 
(16). However, none of these  have been  unambiguously defined. 
A large  amount of information has  accumulated on the physi- 
ological release ofATP and ADP. However, outside of its storage 
in high concentrations in platelet storage granules, little is 
known for UTP concerning its  potential  storage,  release,  and 
activity as an  extracellular molecule. The presence of P,,-pu- 
rinergic receptors that respond to  extracellular  UTP  supports 
the  idea  that his is an  important  extracellular  signaling mol- 
ecule, and potentially provides avenues for studying  the physi- 
ological regulation of extracellular  UTP levels. 
The inositol  lipid signaling cascade is the major second mes- 
senger  response known to be  associated with  activation of P,- 
purinergic receptors (3). Both the P,,- and P,,-purinergic re- 
ceptors  activate phospholipase C in a broad range of tissues. 
However, this is not  the only signaling  response  regulated by 
th se receptors. For example, activation of a P,-purinergic re- 
ceptor that  appears  to be distinct from the p,,-purinergic re- 
ceptor that  activates phospholipase C results  in a decrease  in 
intracellular cyclic AMP accumulation  in some target  tissues 
(17-20). It is also likely that  there  are  other receptors for ex- 
tracellular  adenine  and  uridine nucleotides that  have  not  been 
identified, and we report  here that C6-2B glioma cells express 
a novel receptor that possesses a strict selectivity for uridine 
nucleotides.  Activation of this receptor results in activation of 
phospholipase C through a guanine nucleotide-dependent  per- 
tussis toxin-sensitive  pathway. The existence of a receptor that 
is  activated by uridine nucleotides but  not by adenine nucle- 
otides adds support to the  idea  that  extracellular  UTP  sub- 
serves an  important cell signaling function. 
EXPERIMENTAL PROCEDURES 
Cell Culture and Subcloning“C6-2B  and C6 rat glioma cells and 
HT29  human  colonic  carcinoma  cells  were  grown in Dulbecco’s  modified 
Eagle’s  medium  supplemented  with  DMEM  and 5% fetal bovine  serum 
at 37 “C in a humidified atmosphere of 5% CO,, 95% air. To isolate 
homogeneous  cell  populations  derived  from  single  cloned  cells,  C6-2B 
cells  were  seeded  on  150-cm2  dishes at cell densities  ranging from 10 to 
1000 cellddish.  Attached  isolated  single  cells  were  identified the follow- 
ing  day, and compact clusters  (apparently  clonal) of dividing  cells  were 
isolated  using  7-mm diameter cloning  cylinders.  The  C6-2B  cell  clones 
were transferred to tissue  culture  flasks  and numbered in the order of 
their isolation. 
Inositol Phosphate Assay-Confluent cells  grown  on  12-well  plastic 
plates  (Costar,  Cambridge, MA) were  incubated for 18 h in 0.5 ml of 
4,5)P4, inositol 1,3,4,5-tetrakisphosphate; DMEM,  Dulbecco’s  modified 
Eagle’s  medium. 
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inositol-free DMEM containing 10 pCi/ml [3Hlinositol. The cells  were 
washed twice with HEPES-buffered (pH 7.4) DMEM (WDMEM) and 
preincubated with WDMEM containing 10 m~ LiCl for 15 min before 
challenge with agonists. In those experiments where desensitization 
was studied, the cells  were preincubated with agonist for  20 min prior 
to  addition of LiCl and rechallenged by agonist. Incubations were ter- 
minated by removal of the medium followed  by addition of 5% trichlo- 
roacetic acid. The trichloroacetic acid extracts were neutralized by (3 x 
2 ml) extractions with ethyl ether. Resolution of the individual inositol 
phosphates on Dowex AGl-X8 columns was performed as described 
previously (21). 
Quantitation of Individual Inositol Phosphates by HPLC-Samples 
were prepared as described above except that the cells were labeled 
with 100 pCi of [3Hlinositol in 0.5 ml of DMEM. Individual inositol 
phosphates were  resolved using a Whatman Partisil 10 strong anion- 
exchange  column  (Alltech  Applied  Science,  Deerfield, IL) and an am- 
monium phosphate gradient as described  previously (22). Radioactivity 
was  monitored  on-line with a Radiomatic  Flo-one detector (Radiomatic 
Instruments, Tampa, FL). 
Arachidonic Acid  Release-Confluent  cells  grown  on  12-well plastic 
plates were  labeled  for 6  h with 0.5  pCi of [3Hlarachidonic acid in 0.5 ml 
of  DMEM. The cells  were  washed free of unincorporated radioactivity 
and challenged with agonists for 10 min. Released [3Hlarachidonic acid 
was measured in the cell supernatant as reported previously (23). 
Assay of Phospholipase CActivity in Permeabilized Cells  -[3HlInosi- 
tol-prelabeled cells on 12-well plates were rinsed twice with phosphate- 
buffered saline and permeabilized by a 5-min incubation with 0.2  IU/ml 
streptolysin-0  in assay buffer containing 0.424 m~ CaCl,, 3 m~ MgCl,, 
2 m~ EGTA,  115 m~ KCl,  10 m~ HEPES, and 10 m~ LiCl (pH 7.4) as 
described  previously (8). Streptolysin-0 containing buffer  was  removed 
and  the cells  were incubated in 0.5 ml of assay buffer containing various 
additions. Assays  were terminated by the addition of 0.25 ml of 15% 
trichloroacetic acid and [3Hlinositol phosphates were quantitated as 
described  above. 
Materials-Myo-[2-3Hlinositol(20 Ci/mmol) and [5,6,7,8,9,11,  12,14,- 
15-3Hlarachidonic acid (200 Ci/mmol)  were purchased from  American 
Radiolabelled Chemicals, Inc. (St. Louis, MO). Uridine, UMP, UDP, 
UTP, 5-BrUTP, UDP-glucose, ADP, ATP, dTTP, GDP, GTP, CDP, CTP, 
dUTP,  dCTP,  dGTP, and dATP  were from Boehringer Mannheim. 2-Me- 
SATP and a,P-MeATP  were purchased from Research Biochemicals  Inc. 
(Natick, MA). 2’-Deoxynucleotide diphosphates (dUDP,  dTDP, and 
dCDP)  were purchased from Sigma. Pertussis toxin  was  from List Bio- 
logical Laboratories, Inc. (Cumsell, CA). Streptolysin-0 was obtained 
from  Murex  Diagnostics Limited (Dartford, United Kingdom). Suramin 
was obtained from the Center for Disease Control (Atlanta, GA). 
Data Analysis-Unless stated otherwise, experiments were  per- 
formed with triplicate determinations that differed ~ 1 0 %  from the 
mean. The data were  considered statistically different at p c 0.05 using 
a paired Student’s t  test. 
RESULTS 
Incubation of C6-2B rat glioma cells with UDP resulted  in a 
time-dependent increase  in  intracellular levels of inositol phos- 
phates (Fig. 1). Incubation of these cells with  UTP also elicited 
an  inositol phosphate response that was  temporally and  quan- 
titatively  similar  to  the response observed with UDP. Inositol 
phosphate accumulation in  the presence of either  agonist was 
essentially maximal within 10 min, an effect that  apparently  is 
at least  in  part  due  to h mologous desensitization of the recep- 
tor responding to  the  undine nucleotides (see below). The  time 
course of accumulation of inositol phosphates  in  the presence of 
the  undine nucleotides was  similar to that observed with  the 
muscarinic cholinergic receptor agonist carbachol; the maximal 
effect observed with carbachol was  up  to 2-fold greater  than 
that with  UDP or UTP (Fig. 1). In  contrast to the  stimulatory 
effect of the  undine nucleotides,  incubation of C6-2B cells with 
ATP or ATPyS did not  result  in  increases  in inositol phosphate 
levels. To further  characterize  the effect of undine nucleotides 
on inositol phosphate production,  individual inositol phos- 
phates  in  extracts from  UDP-, carbachol-, and ATP-pretreated 
cells were resolved by HPLC. UDP and carbachol  caused 
marked  increases  in Ins(1,4,5)P3 and its immediate metabolic 
products (Table I and Fig. 2). Although these cells were  labeled 
to  high specific radioactivity with [3H]inositol, ATP had no re- 
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FIG.  1. Time course of inositol phosphate  formation in C6-2B 
glioma cells. [3HlInositol-labeled  C6-2B  cells  were  challenged with 300 
p~ carbachol (A), UTP (W), UDP (O), ATP (O), ATPyS (A), or  vehicle ( 0 ) 
for the indicated times. Incubations were terminated by addition of 5% 
trichloroacetic acid and total inositol phosphates were collected and 
measured as detailed under “Experimental Procedures.” The amount of 
[3Hlinositol phosphates present at t = 0 (-2000  cpm) was subtracted 
from the indicated values. Data represent the mean value of results 
obtained with triplicate assays that are representative of results from 
three different experiments. Error bars were  omitted  for the clarity of 
the figure. 
TABLE I 
Agonist-induced stimulation of inositol trisphosphate and 
tetrakisphosphate 
[3HlInositol  prelabeled  C6-2B  cells  were  challenged  for either 20 s or 
20 min with 300 p~ ATP, UDP, or carbachol. Individual inositol  phos- 
phates were separated by  HPLC as detailed under “Experimental Pro- 
cedures.” Data for  levels of Ins(1,4,5)P3, Ins(1,3,4)P3, and Ins(1,3,4,5)P4 
are presented and  are  the mean 2 S.D. of three determinations. 
Addition Ins(1,4,5)P3  3 4I ,5)P4 
20 s 
CPm 
None  3240 2 280 86 2 35 
ATP 
636 2 286 
3363 2 300  120 2 29 
UDP 
696 2 12 
2961 2 293 
Carbachol 
752 2 53 
25162165  3 62567  2788240
1819 2 433 
20 min 
None  2594 2 206  119 2 93 849 k 316 
ATP  2938 2 645  122 2 16 744 k 23 
UDP  3146 k 609 749 2 43 
Carbachol 37382229  075 36 
2433 -c 435 
4205 k 250 
producible effect on accumulation of individual [3H]inositol 
phosphates during a 20-s, 5-min, or 20-min incubation. The 
lack of effect ofATP was  not due  to hydrolysis of this nucleotide 
since greater  than 95% of added r3H1ATP (100 p ~ )  was recov- 
ered unchanged after incubation in  the presence of C6-2B cells 
for 20 min at 37 “C (data not  shown). Under  the  same condi- 
tions greater  than 95% of added L3H1UTP also  was recovered. 
Observation of inositol phosphate responses to UDP and 
UTP  but  not  to ATP suggested the existence of a  receptor that 
had not been described previously. As such, the response to a 
wide range of nucleotides and to analogs of UTP, ATP, and ADP 
were tested (Fig.  3; Table 11). The most  potent  agonist  identified 
was  UDP which stimulated inositol phosphate accumulation 
with a of 2.3 * 0.5 p~ (Fig. 3). However, 5-BrUTP = 9 
* 3 p ~ )  andUTP = 57 * 10 m) also were full agonists. 
Small effects were observed with UDP-glucose but Uh4P or 
uridine  had no effect. Similarly, 2”deoxy-UTP had no effect on 
inositol phosphate accumulation. The pyrimidine d lTP  caused 
a  concentration-dependent  activation of phospholipase  C, but 
this only occurred at concentrations 100-fold greater than 
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FIG. 2. Effect of UDP and ATP on  accumulation  of  individual 
[%Ilinositol  phosphates. [3HlInositol-prelabeled C6-2B glioma cells 
were challenged for 5 min with vehicle  or with 300 p~ UDP or ATP. 
Individual inositol phosphates were separated by  HPLC and identified 
by co-elution with authentic standards  as indicated. The data  are rep- 
resentative of results obtained from  two separate experiments camed 
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FIG. 3. Concentration-dependent  stimulation of inositol  phos- 
phate  formation by nucleotides  in C62B rat  glioma  and HT29 
human  colon  carcinoma cells. [3HlInositol-labeled cells were incu- 
bated for 20 min in  the presence of the indicated agonists. kf?, data for 
C6-2B  glioma  cells are presented. Individual inositol phosphate concen- 
tration-response curves represent the mean of three to six different 
experiments performed with triplicate samples each. The data  are plot- 
ted as  the percentage of the maximal response obtained in each experi- 
ment with 100 p~ UDP  which ranged from  7,000 to 21,000  cpm. Right, 
results for  HT29 human colon carcinoma cells are presented. The data 
are  the mean of triplicate determinations and  are representative of 
results obtained in  three experiments. Error  bars were omitted for the 
clarity of the figure. 
stimulatory concentrations of  UDP. CTP and GTP had no effect. 
A wide range of compounds  previously  shown to be agonists at 
Pm-, PZy-, Pm-, and P,,-purinergic receptors were tested. None 
of these compounds stimulated inositol lipid hydrolysis  (Table 
11). For example, the potent P,,-receptor agonist 2-MeSATP, the 
potent P,,-receptor agonist a,P-MeATP, the potent P,,-receptor 
agonist 2-MeSADP, and the potent P,,-receptor agonist ATPyS 
all had no effect  on  inositol phosphate accumulation. Similarly, 
the P,-purinergic receptor agonist 2-MeSATP had no  effect  on 
individual inositol phosphates resolved by HPLC after chal- 
lenge of cells for 20 s or 20 min (data not shown and Ref. 20). 
Finally, inositol phosphate responses in a cell line, HT29 hu- 
man colon carcinoma cells,  previously  shown to express P,,- 
TABLE I1 
Effect of nucleotides on inositol phosphate formation in C6-2B cells 
ence of the indicated additions (300 p~ each). Inositol phosphates were 
[3HlInositol-prelabeled cells were incubated for  20 min in  the pres- 
measured as described under "Experimental Procedures." The data rep- 
resent the mean f S.E.  from three to nine different experiments assayed 




1994 2 167 
6229 -c 376 
5-BrUTP 5725 2 333 
UTP 
dTDP 
5415 f 162 
4166 f 458 
d5-BrUTP 
dTTP 
3839 f 179 
3568 2 160 
UDP-glucose 
dUDP 
3317 f 292 
dUTP 
3210 f 360 
UMP 
2127 f 73 
2201 f 28 
Uridine 1905 f 11 
Thymidine 5'-tetraphosphate 2198 f 12 
UTP 2',3'-dialdehyde 
UDP 2',3'-dialdehyde 
2077 2 38 
1983 235 
XTP 2074 f 116 
ATP 
ATPyS 
1885 f 26 
1903 f 142 
2MeSATP 
2MeSADP 
2136 f 107 
ADP@ 
2008 f 103 
ADP 
1956 f 130 
2110 f 91 




1914 f 176 
GTP 
GTPyS 
2183 f 77 
1933 f 28 
GDP 
dATP 
2092 f 121 
dGTP 
1900 e 42 
1959 2 272 
dCTP 1678 29 
Carbachol 8481 f 922 
purinergic receptors were tested for comparison. As is illus- 
trated in Fig. 3, right, ATP and UTP  were  effective agonists in 
HT29  cells under conditions where, in C6-2B  cells, they were 
either less potent than UDP (UTP) or were without effect 
(ATP).  UDP was approximately 100-fold less potent than UTP 
in HT29  cells. 
Simultaneous challenge of C6-2B  cells with UDP and carba- 
chol resulted in inositol phosphate accumulation that was es- 
sentially the  sum of the accumulations observed in the pres- 
ence of either agonist alone (Fig. 4). In  contrast, simultaneous 
challenge of cells with UTP and UDP resulted in no greater 
inositol phosphate accumulation than accumulation observed 
with either agonist alone, suggesting that these compounds 
activate the same receptor. ATP alone had no  effect  on inositol 
phosphate accumulation and no significant effect of ATP was 
observed when combined with UDP,  UTP, or carbachol (Fig. 4). 
Cross-desensitization experiments also were carried out to 
examine whether ATP interacts with the receptor that is acti- 
vated by UDP and UTP. These experiments took advantage of 
the fact that receptor-stimulated accumulation of total L3H1i- 
nositol phosphates is negligible in  the absence of LiCl. Thus, 
cells  were preincubated, i.e. desensitized, with agonist in  the 
absence of LiCl and inositol phosphate accumulation in re- 
sponse to a second drug challenge was assessed by co-addition 
of agonist and LiCl. Preincubation of C6-2B cells with UDP or 
UTP  for  20 min resulted in a marked decrease in subsequent 
responsiveness to both UTP and UDP (Fig. 5) but a much 
smaller decrease in response to carbachol. In  contrast, prein- 
cubation of cells with ATP had no inhibitory effect  on subse- 
quent responsiveness to carbachol, UDP, or UTP. Taken to- 
gether with the additivity experiments, these results indicate 
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FIG. 4. Additivity of nucleotide-  and  carbachol  (CARB)-stimu- 
lated  inositol  phosphate  formation in C6-2B cells. [3HlInositol- 
labeled  cells were incubated  with the indicated  agonists  or  combination 
of agonists (300 p~ each) for 20 min, trichloroacetic acid (5%) was 
added,  and  inositol  phosphate  formation was quantitated as indicated 
under "Experimental Procedures." The amount of [3Hlinositol phos- 
phates present at t = 0 (52300 cpm) was subtracted from the indicated 
values. The data are the mean z S.D. of triplicate determinations. *, 
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FIG. 5. Desensitization of agonist-stimulated inositol phos- 
phate  formation  in CS2B cells. [3HlInositol-labeled  cells were pre- 
incubated  for 20 min  with 300 p~ UDP, UTP, or ATP or in the absence 
of any drug. The cells  were  rapidly washed and incubated for an addi- 
tional 10 min with 300 p~ carbachol (wide  strips),  300 p~ UDP (open 
bar), or 300 p~ UTP (narrow stripes) in the presence of 10 m~ LiC1. The 
results are plotted as the percent of agonist responses  obtained  with 
cells that were  preincubated in the absence of any added drug. Data 
represent the mean S.D. of triplicate  determinations. *, p < 0.01. 
that UDP  and  UTP  act at a common receptor at which ATP is 
not an effective ligand. 
Reactive blue  and  suramin  have  been proposed to competi- 
tively inhibit  adenine nucleotide receptors  in a number of tis- 
sues (3). Experiments were carried  out to examine  the effect of 
reactive blue and  suramin on UDP-stimulated inositol phos- 
phate  formation  in C6-2B cells. Suramin (3-50 p) caused a 
parallel shift to the  right of the concentration-effect curve of 
UDP  without affecting maximal  response  to  UDP  (Fig. 6; data 
not shown).  Because suramin  concentration  in excess of 50 p 
also resulted in inhibition of carbachol-stimulated inositol 
phosphate  formation in C6-2B cells (data  not shown), a detailed 
Schild analysis of the effect of suramin on UDP  response  was 
not performed. Unlike  suramin,  reactive blue (3-50 p) caused 
. .  
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FIG. 6. Inhibition of  UDP-stimulated  inositol  phosphate  forma- 
tion by suramin. [3HlInositol-labeled cells were preincubated for 5 
min without or  with the indicated  concentration of suramin  and  chal- 
lenged  with  UDP  for an additional 15  min.  The r sults are plotted a8 the 
percentage of the maximal  response  obtained with UDP at each  given 
suramin concentration.  The data represent the mean 2 S.D. of results 
obtained in four  different  experiments. 
a noncompetitive inhibition of UDP responses, as judged by 
decreases of the  maximal effect of UDP  with negligible changes 
of the  concentration of agonist producing  half-maximal effects 
(data not  shown). 
Receptor-mediated regulation of phospholipase C by a broad 
range of extracellular  stimuli  has been shown to involve G- 
proteins. At  least two general  mechanisms  are  apparently  in- 
volved, one  involving members of the  pertussis toxin-insensi- 
tive G, family of G-proteins (24) and one involving pertussis 
toxin-sensitive Gi or Go (25-27). C6-2B glioma cells were  incu- 
bated  with  various  concentrations of pertussis toxin and  re- 
sponsiveness to carbachol and  UDP were subsequently  meas- 
ured.  Pretreatment of cells with  pertussis toxin resulted  in only 
small (0-20%) decreases  in carbachol-stimulated  inositol phos- 
phate  accumulation (Fig. 7, A and B). In  contrast, UDP- and 
UTP-stimulated inositol phosphate  accumulation  was reduced 
by up  to 80% by pretreatment of C6-2B cells with maximally 
effective concentrations of pertussis toxin. The effect of pertus- 
sis toxin was observed as a decrease  in  response to maximally 
effective concentrations of UDP with little or no change in 
apparent potency (Fig. 7B 1. 
The  data  with  pertussis  toxin-treated cells suggested  that 
the receptor for UDP coupled to a G-protein to regulate phos- 
pholipase C. This possibility was examined  directly by measur- 
ing inositol lipid hydrolysis in streptolysin-0-permeabilized 
C6-2B cells. GTPyS produced a concentration-dependent in- 
crease  in inositol phosphate formation  (Fig. 8). Addition of UDP 
alone had no effect on enzyme activity. However, incubation of 
membranes  with 100 p~ UDP  in  the presence of increasing 
concentrations of GTPyS  resulted  in a marked  stimulation over 
the effect observed with guanine nucleotide alone. The for 
UDP for augmentation of inositol phosphate formation in  the 
presence of 30 p GTPyS was approximately 20 p (data not 
shown). 
The  data  presented  thus  far  indicate  that a novel receptor for 
uridine nucleotides activates phospholipase C in C6-2B glioma 
cells. The possibility that this receptor also  activates  another 
second messenger  signaling  response  was considered. Phospho- 
lipid pools were prelabeled with  [3Hlarachidonate as described 
under  "Experimental Procedures." Agonist-promoted release of 
[3Hlarachidonic  acid,  supposedly  occurring as a consequence of 
activation of phospholipase 4, was  then  studied.  Incubation of 
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FIG. 7. Effect of pertussis toxin (PTX) on inositol  phosphate  formation. C6-2B cells  were  labeled  for 18 h with 5 pCi of [3H]inositol in 0.5 
ml of inositol-free DMEM containing the indicated concentrations of pertussis toxin (panel A)  or with 30 n g / d  pertussis toxin (panel B).  The data 
are the mean 2 S.D. of triplicate determinations. Panel A, the effects of 300 p~ carbachol, UDP, and UTP on inositol phosphate accumulation were 
determined. The data  are plotted as the percent of maximal stimulation observed with each drug in control  cells. Panel B, the response to the 
indicated concentrations of UDP was quantitated  in control  cells or cells pretreated for 18 h with 30 ng/ml pertussis toxin. *, p e 0.05. 
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FIG. 8. Guanine  nucleotide-dependent  inositol  lipid  hydrolysis 
in streptolysin-0-permeabilized CB2B glioma cells. C6-2B cells 
were  permeabilized with streptolysin-0 and [3Hlinositol phosphate ac- 
cumulation was measured as described under “Experimental Proce- 
dures.” Assays  were in the presence of the indicated concentrations of 
GTPyS with (0) or without (0) 100 p~ UDP. The data  are the mean 2 
S.D. of triplicate determinations and the  results  are representative of 
those obtained in  three  separate experiments. *, p e 0.01. 
cells with UTP,  UDP, or carbachol (Fig. 9; data not shown) all 
resulted in a concentration-dependent release of [3H]arachi- 
donic acid. The potency of these agonists was similar to that 
observed in measurements of [3Hlinositol phosphate accumu- 
lation. Negligible increases in [3H]arachidonic acid release 
were  observed in  the presence of  ATP. 
Experiments were carried out to determine whether the uri- 
dine nucleotide-selective response could be observed in cells 
expanded from single cells  cloned  from the C6-2B  cell line as 
described under “Experimental Procedures.” Eight different 
subclones were isolated and  their inositol phosphate responses 
measured. Seven of these subclones  (Clones 1,2,3,4,6,7,  and 
8) were  morphologically similar to the parent cells that were 
previously studied in detail. Clone 5 was markedly different 
morphologically. These cells  were  much smaller and possessed 
many long  processes.  However, all eight of the subclones  ex- 
pressed receptors that responded to UDP with a marked in- 
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FIG. 9. Receptor-stimulated [W]arachidonic acid release in 
C&2B glioma cells. [3HlArachidonic  acid-prelabeled  cells  were incu- 
bated for 10 min with the indicated additions. [3HlArachidonic acid 
released into the medium was quantitated as described under “Experi- 
mental Procedures.” The data  are  the mean * S.D. of results obtained 
with triplicate determinations and are representative of results ob- 
tained in four separate experiments. 
crease in inositol phosphate accumulation (data for 5 clones are 
presented in Fig. 10, left) .  The inositol phosphate response to 
ATP was negligible in  all of these subclones. 
C6-2B rat glioma  cells represent a subclone that was origi- 
nally isolated from  C6  glioma  cells by de Vellis and Brooker 
(28). Inositol phosphate responses to nucleotides also were 
tested in C6 glioma  cells that were obtained from the American 
Type Culture Collection. In contrast to the lack of response 
observed with C6-2B  cells, ATP and ATPyS markedly stimu- 
lated inositol phosphate accumulation in C6 glioma  cells (Fig. 
10, right), and the pharmacological  specificity  for enhancement 
of inositol lipid hydrolysis in C6  glioma  cells  (ATP = UTP > 
ATPyS >> UDP) was similar to that observed in HT29 human 
colon carcinoma cells (Fig. 3, right) and for  P,,-purinergic re- 
ceptors in many target cells.  Carbachol,  which markedly stimu- 
lated inositol phosphate accumulation in C6-2B glioma cells 
(Fig. 11, had no reproducible effect on accumulation in C6 
glioma  cells (Fig. 10, right). 
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FIG. 10. Effect  of UDP and ATP on inositol  phosphate  forma- 
from the American Type Culture  Collection. Left, the effect of UDP 
tion in  subclones  of  C6-2B cells and in C6 glioma cells obtained 
(filled  symbols) and ATP (open  symbols) on  inositol phosphate forma- 
tion was determined with C6-2B  cell populations expanded from  five 
different cloned single cells as detailed under "Experimental Proce- 
dures." The data  are  the mean of triplicate determinations and are 
representative of results from two different experiments with each 
clone. Right, the effect of ATP, UTP, UDP, ATP+, and carbachol on 
inositol phosphate accumulation was determined in C6 glioma cells 
obtained from the American w e  Culture Collection. 
DISCUSSION 
A  receptor that  has  not been described previously exists on 
C6-2B rat glioma cells. This receptor, which stimulates inositol 
lipid  hydrolysis,  shows a strict selectivity for uridine nucleoti- 
des  and is activated only nominally or not at all by  ATP,  ADP, 
or  analogs of these  adenine nucleotides. This receptor can be 
clearly  differentiated from the P,,-purinergic receptor, which is 
found on  many  target  tissues.  The C6-2B cell receptor is acti- 
vated by  UDP, and UTP is a less  potent full  agonist. ATP and 
ATPyS have  little  or no effect. In  contrast, ATP, ATPyS, and 
UTP  are  the most  potent agonists at P,,-purinergic receptors; 
UDP has been  shown to be much less potent than  UTP (Fig. 3, 
right, and Ref. 5) or to be without effect (8) a t  these receptors. 
Several different types of experiments including  those  examin- 
ing  additivity of responses  or cross-desensitization also con- 
firmed that  the receptor on the C6-2B glioma cells does not 
recognize adenine nucleotides. 
A  full  delineation of the  structure-activity  relationships for 
nucleotide-activated  inositol phosphate formation in C6-2B cells 
was limited by the lack of availability of a wide range of py- 
rimidine  nucleotides. UDP was the most  potent and effective of 
the nucleotides studied.  The presence of a y-phosphate, i.e. UTP, 
resulted  in a reduced potency of approximately 30-fold. Replace- 
ment of the y-phosphate of UTP  with glucose (UDP-glucose) re- 
sulted  in  further decreases of both potency and efficacy.  How- 
ever, increased potency relative to UTP was observed with 
substitution of bromo at position 5 of the pyrimidine ring of UTP 
(5-BrUTP). In  contrast,  substitution f a keto group for the -NH, 
at position 4 (CTP, CDP) resulted  in  total loss of activity. 2'- 
Deoxynucleotides have no effect on P,,-purinergic receptors (8), 
and similarly, the receptor on C6-2B cells was  not activated by 
dUTP at any concentration tested  up  to 1 m ~ .  However, as was 
observed with 5-BrUTP, 5-bromo substitution of dUTP (2'-de- 
oxy-5-BrUTP) resulted  in  an  increase  in activity. Some activity 
(-50% of maximal stimulation observed with UDP) was ob- 
served with d"P and  dTDP, which can be considered as 
5-methyl analogs of dUTP  and dUDP, respectively. Thus,  sub- 
stitution at position 5 of the pyrimidine ring with bromo or -CH, 
resulted  in  enhanced activity of the  uridine  triphosphate  ana- 
logs. These results  suggest  that compounds such as 5-BrUDP or 
5-MeUDP will be very potent  agonists at this receptor. 
Specific antagonists for receptors for extracellular nucleoti- 
des  have  not been identified. However, suramin  and reactive 
blue, which have a broad range of pharmacological activities 
previously have been shown to competitively block P,-puriner- 
gic receptors in a number of tissues (3). Suramin also blocks the 
receptor for uridine nucleotides on C6-2B glioma cells, al- 
though at higher concentrations an  apparently nonspecific in- 
hibition of the inositol lipid  hydrolysis occurred. 
Effects of extracellular  uridine  and  uracil nucleotides have 
been reported previously. These responses range from relax- 
ation or contraction of various smooth muscle preparations  to 
inhibition of 0, uptake,  stimulation of glucose output,  and  en- 
hancement of superoxide  formation (16). Difficulties inherent 
in defining  receptors for extracellular nucleotides on heteroge- 
neous tissue  preparations  have compromised classification of 
these responses, but it is likely that  many of these effects are 
mediated by  P,,-purinergic receptors. That is, a receptor that is 
activated by both UTP and ATP is involved. However, PZu- 
purinergic  receptors apparently do not completely account for 
the response to uridine nucleotides in  peripheral  tissues  and 
Seifert and Schultz (16)  have proposed the existence of a sepa- 
rate class of pyrimidinergic  receptors. The pharmacological se- 
lectivities of responses in several vascular smooth muscle 
preparations were not  the  same as those of the P,,-purinergic 
receptor (10-12), and  in  several cases the response  also can  be 
distinguished  from that observed in C6-2B glioma cells since 
UMP, uridine, and CTP all were shown to produce vascular 
responses similar to those of UTP or UDP (29-33). Support for 
the existence of a receptor for UTP  that is not activated by  ATP 
also has come from studies  in which responses to  UTP  and ATP 
in a heterogeneous tissue could be differentially blocked by 
pretreatment  with supposed antagonists  and by experiments  in 
which cross-desensitization did not occur between the two 
nucleotides  (10, 11, 34). 
The  data obtained with C6-2B glioma cells places the exist- 
ence of a selective receptor for uridine nucleotides on firm 
ground. With the pharmacological specificity defined here  in 
hand,  it will be important  to more  clearly delineate  the physi- 
ological role of this receptor in various tissues.  These  results 
together  with  the  large  amount of existing information on P2"- 
purinergic  receptors indicate  that  there  are at least two differ- 
ent receptors that respond to  extracellular uracil  nucleotides. 
Relatively little is known about  the  regulation of the  storage 
and release of these nucleotides, although platelet storage 
granules  are a rich  source of UTP  and  UTP is released  upon 
platelet  activation (16, 35). Resting levels of extracellular  UTP 
in solid tissues  are  in  the  range of 1 x M (16, 36). A multi- 
plicity and widespread  existence of receptors for uridine nucle- 
otides and  the presence of nucleotides at  concentrations ca- 
pable of activating  these receptors  suggests that  the  regulated 
release of uridine nucleotides will prove to be a physiologically 
important process. 
The second messenger  responses regulated by the receptor 
for uridine nucleotides on C6-2B glioma cells followed the gen- 
eral properties observed for many receptors  including the  mus- 
carinic cholinergic receptor on the  same cells. Streptolysin-0- 
permeabilized cells were used to  illustrate directly that  this 
receptor  promotes guanine nucleotide-dependent  activation of 
phospholipase C. The large sensitivity of the intact cell re- 
sponse to inactivation by pertussis toxin places these receptors 
into  the subclass of receptors that couple to phospholipase C 
through Gi or Go  (25-27). Several recent  reports suggest that 
activation of phospholipase  C in  this  pathway occurs as a con- 
sequence of release of &-subunits from the involved G-protein 
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(3740). Our  assumption  is  that  the activation of arachidonate 
release by this uridine nucleotide receptor is phospholipase 
&-mediated and occurs secondarily to activation of phospho- 
lipase C with subsequent Ca2+ mobilization and activation of 
protein kinase C; however, this has  not been  formally proven. 
In  addition to the  uridine nucleotide-selective receptor, we 
have observed previously that activation of a P,-purinergic 
receptor on C6-2B glioma cells results  in inhibition of adenyl- 
ylcyclase and a decrease in  intracellular cyclic AMP levels (20). 
This receptor does not  activate phospholipase C and  thus is 
apparently different from the P,,-purinergic receptods) found 
on many  target  tissues which activates phospholipase C but 
does not  regulate adenylylcyclase activity. Lin and  Chuang (41) 
have  reported  that ATP stimulates inositol phosphate  and Ca" 
accumulation in C6 glioma cells, and we have confirmed their 
results  with C6 glioma cells obtained from the American Type 
Culture Collection (Fig. 10, right). In  contrast, we have been 
unable to observe stimulation of inositol lipid hydrolysis by 
ATP or its analogs in C6-2B glioma cells, which are a subclone 
originally  isolated from the RGC6 glioma cell line by deVellis 
and Brooker (28). We also  isolated eight additional subclones 
from C6-2B glioma cells. All of these expressed a phospholipase 
C-linked receptor that  was  activated by UDP but not by ATP. 
Earlier  studies on the P-adrenergic  receptorkyclic AMP system 
had revealed differences among the  signaling properties of the 
various C6 cell (including C6-2B cells) subclones (42451, and 
although carbachol  markedly stimulated inositol phosphate ac- 
cumulation in C6-2B glioma cells, no reproducible effect of mus- 
carinic  receptor stimulation  was observed in C6 cells obtained 
from the American Type Culture Collection. 
In summary, a phospholipase  C-activating  receptor for UDP 
and  UTP  has been identified on C6-2B rat glioma cells. Based 
on the properties of second messenger  responses, this receptor 
must be structurally  related  to  the superfamily of seven trans- 
membrane-spanning G-protein-linked receptor proteins. The 
recently cloned P2,- (46)  and P,,,-purinergic receptors (47) have 
amino acid sequences that predict  seven transmembrane  span- 
ning motifs. However, they  express a low sequence homology 
with each other and suggest the existence of two new sub- 
classes of G-protein-linked receptors. Our  anticipation is that 
the receptor  described here will fall structurally  into a class of 
receptors  with structures containing only low sequence homol- 
ogy to PZypurinergic  receptors and  perhaps somewhat higher 
homology to  the so-called P,,-purinergic receptods)  that is ac- 
tivated by both UTP  and ATP. Since only uridine nucleotides are 
agonists at the receptor studied  here, we propose that it be called 
a uridine nucleotide receptor. Molecular cloning of this uridine 
nucleotide  receptor will be required  to  establish  whether  it is a 
member of a new class of receptor proteins or is a second member 
of the subfamily of P,,-purinergic receptor-like proteins. 
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